Investigational drug · Phase 2
AAVB-039
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Stargardt Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AAVB-039"
First trial start
2025
Sep 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AAVB-039", any sponsor or status.
Conditions studied
As listed on its trial records.
- Stargardt Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "AAVB-039" as an intervention, largest first.
AAVantgarde Bio SrlIndustry
NCT07161544 · 75 participants (planned) · Start Sep 29, 2025 · Primary completion Jul 2032
Drug: AAVB-039 · For: Stargardt Disease
Sites: Phoenix, Arizona; Los Angeles, California; Jacksonville, Florida · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Stargardt Disease
- ALK-001C20-D3-Retinyl Acetate, C20 Deuterated vitamin APhase 33 trials
Alkeus Pharmaceuticals, Inc. · Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
- OCU410STPhase 31 trial
Ocugen · Stargardt Disease
- ACDN-01Phase 21 trial
Ascidian Therapeutics, Inc · Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.